SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong Sells 8,500 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $5.62, for a total transaction of $47,770.00. Following the completion of the transaction, the chairman owned 3,532,622 shares in the company, valued at $19,853,335.64. This trade represents a 0.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total transaction of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total value of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total transaction of $44,540.00.
• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total value of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.00, for a total value of $87,365.00.

SOPHiA GENETICS Price Performance

SOPH stock opened at $5.68 on Wednesday. The company has a market capitalization of $476.50 million, a PE ratio of -10.92 and a beta of 0.96. SOPHiA GENETICS SA has a one year low of $2.92 and a one year high of $6.30. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The company’s fifty day moving average price is $5.19 and its 200-day moving average price is $5.00.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently modified their holdings of SOPH. Hennion & Walsh Asset Management Inc. purchased a new position in SOPHiA GENETICS during the 2nd quarter worth approximately $567,000. Royal Bank of Canada raised its holdings in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares during the last quarter. Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS during the first quarter worth $1,772,000. Principal Financial Group Inc. lifted its position in SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the period. Finally, Hodges Capital Management Inc. acquired a new position in SOPHiA GENETICS during the first quarter valued at $2,157,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on SOPH. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, SOPHiA GENETICS currently has a consensus rating of “Hold” and a consensus price target of $7.50.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.